Your search matched 172 results
With a low public tolerance to drug pricing in the recent news, two companies joined forces to help combat the difficult subject when discussing pharmaceutical pricing: transparency.
How could the recent impeachment inquiry effect drug pricing legislation on the Hill?
This month policies aimed at lowering drug prices are back on the table.
With a global pandemic, rising inflation, and continued political pressures, drug pricing will undoubtedly remain a big focus in 2022.
COVID-19 Kicks Drug Pricing Down the Road | In The Media
Meg Alexander, head of the reputation and risk management practice at Syneos Health, and Jeff Stewart, managing director at Syneos Health Consulting, teamed up with MM&M to discuss implications of COVID-19 and the upcoming US election on drug pricing.
Over the past several years, we have all grown accustomed to the drug-pricing-war headlines.
Drug Pricing Regulatory Action Near Certain | In The Media
Drug pricing regulation is on the horizon and it could affect everything from marketing to pipelines.
While federal drug pricing reform in the Build Back Better Act (BBBA) is stalled at the Senate, states are taking the issue into their own hands.
No, the CEOs of Pfizer and Regeneron are not shaking hands and working it out following their heightened rhetoric about drug prices two years ago.
Instead, we’ve got a look at some of the drug pricing bills that could make it to the floor of the U.S.
The industry and the Department of Health and Human Services presented different visions of what greater pricing transparency looks like in the future, complete with separate proposals of how and what information should be shared with consumers.
Leslie Isenegger, Principal Strategist for Reputation & Risk Management Practice at inVentiv Health Communications, addresses the topic of orphan drug pricing in this article published in Pharmaceutical Executive.
What impact could the 4 healthcare-related executive orders that President Trump signed last Friday (July 24) have on the pharma industry.
When Drug Pricing Communications Go Wrong | In The Media
Effective value communications in an era increasingly defined by an increased attention to price.
An update on the latest developments in Washington critical to Pharma leaders.
What to Expect on Drug Pricing in the Democratic Trifecta | Perspectives
President Joe Biden hit the ground running, signing 30 executive orders on healthcare.
The Institute for Clinical and Economic Review (ICER) recently published the white paper “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.”
PUSHBACK ON RARE DRUG PRICES: NOT SO RARE AFTER ALL | In The Media
There’s no doubt the “pricing crisis,” has taken a heavy toll on the reputation of the biopharmaceutical industry.
Department of Health and Human Services calls for pharmaceutical companies to display drugs’ list prices in their TV commercials.
Policymakers continue their focus on drug pricing and may also have eyes for changes to the Orphan Drug Act.
Fancy a Pharma Chinwag? | Blog
We are gobsmacked at the amount of pharma pricing activity following the release of President Trump’s “Blueprint” to lower drug prices.
As drug pricing continues to be under the microscope, it’s a tough environment for drug makers.
This month, we’ve seen a flurry of activity that confirms Washington will be focused on drug pricing this summer, and it’s coming from all directions: Congress, the Biden Administration, and Courts.
Responding to rampant criticism of rising drug prices, pharma giant Eli Lilly will begin selling an authorized generic of its preeminent insulin therapy, Humalog, at half-price.
President Trump and HHS Secretary Azar gave a slightly delayed, much anticipated speech on the Administration’s Blueprint to lower drug prices.
In this Pharmafield article, Monique Martin and Doug Niven talk about the gradual but sustained increase in prices of new orphan drugs in Europe.
CVS Health recently announced a new tool available to pharmacists and patients.
The U.S. | Blog
Democrats have revealed that the next major legislative package—colloquially known as the infrastructure package—will likely include provisions to lower prescription drug prices.
These high prices make is near impossible for poorer countries to afford these drugs or make them available at all.
Summer is coming to a close, but actions around drug pricing and access just keep heating up.